Abstract
We describe the results of a prognostic factor analysis in patients with metastatic gastric cancer treated with an intensive weekly regimen: cisplatin 40 mg/m2, epirubicin 35 mg/m2, 5-fluorouracil 500 mg/m2, 6S-stereoisomer of leucovorin at a dose of 250 mg/m2, and glutathione at a dose of 1.5 g/m2, with the support of G-CSF, 5 μg/kg, from the day after to the day before each chemotherapy administration. The variables used for analysis were: age, sex, ECOG performance status, a weight loss > 10%, site of primary tumor, metastatic disease and number of sites, disease free interval patients undergone curative resections only), dose intensity of the three drugs, expressed as percentage of planned dose intensity (80-100% versus <79%), initial hemoglobin, albumin, SGOT, SGPT, LDH, alkaline phosphatase. The variables predictive of response were: ECOG performance status (p = 0.04), weight loss (p = 0.0042), disease free survival (p = 0.002) and dose intensity of the three drugs (p = 0.0038). Regarding response of the primary tumor, site (cardia versus other sites) was the only prognostic factor (p = 0.0028). From these data, clinical condition of the patients and cytotoxic drug doses seem to be the main prognostic features. We recommend description of these factors in reports of phase II studies of new treatments.
| Original language | English |
|---|---|
| Pages (from-to) | 79-83 |
| Number of pages | 5 |
| Journal | GI Cancer |
| Volume | 3 |
| Issue number | 1 |
| Publication status | Published - 1999 |
Fingerprint
Keywords
- Gastric cancer
- Prognostic factor to chemotherapy
- Toxicity
ASJC Scopus subject areas
- Gastroenterology
- Oncology
Cite this
Predictors of response to an intensive weekly chemotherapy in advanced gastric cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). / Cascinu, S.; Labianca, R.; Barni, S.; Frontini, L.; Ligi, M.; Del Ferro, E.; Silva, R. R.; Pancera, G.; Pessi, M. A.; Giordani, P.; Agostinelli, R.; Catalano, V.; Rocchi, M. B L; Ghiandoni, G.; Luporini, G.; Catalano, G.
In: GI Cancer, Vol. 3, No. 1, 1999, p. 79-83.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Predictors of response to an intensive weekly chemotherapy in advanced gastric cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)
AU - Cascinu, S.
AU - Labianca, R.
AU - Barni, S.
AU - Frontini, L.
AU - Ligi, M.
AU - Del Ferro, E.
AU - Silva, R. R.
AU - Pancera, G.
AU - Pessi, M. A.
AU - Giordani, P.
AU - Agostinelli, R.
AU - Catalano, V.
AU - Rocchi, M. B L
AU - Ghiandoni, G.
AU - Luporini, G.
AU - Catalano, G.
PY - 1999
Y1 - 1999
N2 - We describe the results of a prognostic factor analysis in patients with metastatic gastric cancer treated with an intensive weekly regimen: cisplatin 40 mg/m2, epirubicin 35 mg/m2, 5-fluorouracil 500 mg/m2, 6S-stereoisomer of leucovorin at a dose of 250 mg/m2, and glutathione at a dose of 1.5 g/m2, with the support of G-CSF, 5 μg/kg, from the day after to the day before each chemotherapy administration. The variables used for analysis were: age, sex, ECOG performance status, a weight loss > 10%, site of primary tumor, metastatic disease and number of sites, disease free interval patients undergone curative resections only), dose intensity of the three drugs, expressed as percentage of planned dose intensity (80-100% versus <79%), initial hemoglobin, albumin, SGOT, SGPT, LDH, alkaline phosphatase. The variables predictive of response were: ECOG performance status (p = 0.04), weight loss (p = 0.0042), disease free survival (p = 0.002) and dose intensity of the three drugs (p = 0.0038). Regarding response of the primary tumor, site (cardia versus other sites) was the only prognostic factor (p = 0.0028). From these data, clinical condition of the patients and cytotoxic drug doses seem to be the main prognostic features. We recommend description of these factors in reports of phase II studies of new treatments.
AB - We describe the results of a prognostic factor analysis in patients with metastatic gastric cancer treated with an intensive weekly regimen: cisplatin 40 mg/m2, epirubicin 35 mg/m2, 5-fluorouracil 500 mg/m2, 6S-stereoisomer of leucovorin at a dose of 250 mg/m2, and glutathione at a dose of 1.5 g/m2, with the support of G-CSF, 5 μg/kg, from the day after to the day before each chemotherapy administration. The variables used for analysis were: age, sex, ECOG performance status, a weight loss > 10%, site of primary tumor, metastatic disease and number of sites, disease free interval patients undergone curative resections only), dose intensity of the three drugs, expressed as percentage of planned dose intensity (80-100% versus <79%), initial hemoglobin, albumin, SGOT, SGPT, LDH, alkaline phosphatase. The variables predictive of response were: ECOG performance status (p = 0.04), weight loss (p = 0.0042), disease free survival (p = 0.002) and dose intensity of the three drugs (p = 0.0038). Regarding response of the primary tumor, site (cardia versus other sites) was the only prognostic factor (p = 0.0028). From these data, clinical condition of the patients and cytotoxic drug doses seem to be the main prognostic features. We recommend description of these factors in reports of phase II studies of new treatments.
KW - Gastric cancer
KW - Prognostic factor to chemotherapy
KW - Toxicity
UR - http://www.scopus.com/inward/record.url?scp=0033025555&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033025555&partnerID=8YFLogxK
M3 - Article
VL - 3
SP - 79
EP - 83
JO - GI Cancer
JF - GI Cancer
SN - 1064-9700
IS - 1
ER -